The metabolic revolution
Compounds such as Semaglutide, Tirzepatide, and Retatrutide have captured worldwide scientific attention for their results in weight regulation, glycemic control, and metabolic health studies.
What are GLP-1 and GIP receptors?
GLP-1 (Glucagon-Like Peptide-1): a peptide produced in the gut in response to food intake. It stimulates insulin secretion, inhibits glucagon, delays gastric emptying, and regulates appetite from the hypothalamus.
GIP (Glucose-Dependent Insulinotropic Polypeptide): a complementary gut peptide. It enhances insulin secretion, participates in adipose tissue metabolism, and has effects on bone and the central nervous system.
GCG (Glucagon): regulates hepatic glucose production and energy metabolism.
The leading compounds under research
Semaglutide — first-generation GLP-1 agonist
Mechanism: a selective GLP-1 receptor agonist. It has a long 7-day half-life due to fatty acid modification. Research area: glycemic control and weight regulation.
Tirzepatide — dual GLP-1/GIP agonist
Mechanism: simultaneously activates GLP-1 and GIP receptors, producing synergistic effects on energy metabolism. Studies published in the New England Journal of Medicine reported greater weight reductions than pure GLP-1 agonists. View Tirzepatide 10mg.
Retatrutide — triple GLP-1/GIP/GCG agonist
Mechanism: adds glucagon receptor activation to the dual mechanism, stimulating thermogenesis and fatty acid oxidation. Its phase II studies published in 2023 showed the most pronounced results reported to date. View Retatrutide 10mg.
Cagrilintide — amylin analog
Mechanism: amylin regulates gastric emptying and satiety independently of the GLP-1 axis. Cagrilintide is a long-acting synthetic analog. Its combination with semaglutide (CagriSema) has generated major scientific interest. View Cagrilintide 5mg.
Compound comparison
- Semaglutide: GLP-1 receptor, single mechanism, first generation.
- Tirzepatide: GLP-1 and GIP receptors, dual mechanism, second generation.
- Retatrutide: GLP-1, GIP, and GCG receptors, triple mechanism, third generation.
- Cagrilintide: amylin receptor, independent, complementary mechanism.
Why is this field so relevant?
More than 1 billion people live with obesity globally. In Peru, the prevalence of overweight and obesity exceeds 60% of the adult population. This has made metabolic research one of the most heavily invested scientific fields worldwide.
Current state of research
- Synergistic combinations: Tirzepatide + Cagrilintide.
- New indications: cardiovascular, renal, and neurological effects.
- Oral formulations: oral bioavailability of GLP-1 peptides.
- Central mechanisms: role of GLP-1 receptors in the nervous system.
Conclusion
GLP-1 agonists and their derivatives represent one of the most dynamic areas of peptide research. BioPeptideX offers these compounds with 99% verified purity, a complete COA, and cold-chain shipping across Peru and LATAM.